The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
PD-L1
Open accessAbstract
Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer. Under physiological conditions, the PD-1/PD-L1 interaction is essential in the development of immune tolerance preventing excessive immune cell activity that can lead to tissue destruction and autoimmunity. PD-L1 expression is an immune evasion mechanism exploited by various malignancies and is generally associated with poorer prognosis. PD-L1 expression is also suggested as a predictive biomarker of response to anti-PD-1/PD-L1 therapies; however, contradictory evidence exists as to its role across histotypes. Over the years, anti-PD-1/PD-L1 agents have gained momentum as novel anticancer therapeutics, by inducing durable tumour regression in numerous malignancies including metastatic lung cancer, melanoma and many others. In this review, we discuss the immunobiology of PD-L1, with a particular focus on its clinical significance in malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
Tissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,121
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin, J., Han, G., Schalper, K. A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R., LoRusso, P., & Rimm, D. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3638 · Cited by 837
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678
Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & Tokura, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 667
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2477 · Cited by 665
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 645
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 627
T-Cell Tolerance: Central and Peripheral
Xing, Y., & Hogquist, K. A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006957 · Cited by 576
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
Probst, H. C., McCoy, K., Okazaki, T., Honjo, T., & van den Broek, M. (2005) · Nature Immunology · doi:10.1038/ni1165 · Cited by 554
Kaufmann, D. E., Kavanagh, D. G., Pereyra, F., Zaunders, J. J., Mackey, E. W., Miura, T., Palmer, S., Brockman, M., Rathod, A., Piechocka-Trocha, A., et al. (2007) · Nature Immunology · doi:10.1038/ni1515 · Cited by 524
Prognostic and predictive value of PDL1 expression in breast cancer
Sabatier, R., Finetti, P., Mamessier, E., Adelaide, J., Chaffanet, M., Ali, H. R., Viens, P., Caldas, C., Birnbaum, D., & Bertucci, F. (2015) · Oncotarget · doi:10.18632/oncotarget.3216 · Cited by 508
Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X.-G., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 495
Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2731 · Cited by 485
Autoregulation of E-cadherin expression by cadherin–cadherin interactions
Conacci-Sorrell, M., Simcha, I., Ben-Yedidia, T., Blechman, J., Savagner, P., & Ben-Ze'ev, A. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200308162 · Cited by 474
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Goodman, A., Patel, S. P., & Kurzrock, R. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.168 · Cited by 461
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., et al. (2016) · Hepatology · doi:10.1002/hep.28710 · Cited by 440
Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22588 · Cited by 438
Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1
Bivona, T. G., Pérez de Castro, I., Ahearn, I. M., Grana, T. M., Chiu, V. K., Lockyer, P. J., Cullen, P. J., Pellicer, A., Cox, A. D., & Philips, M. R. (2003) · Nature · doi:10.1038/nature01806 · Cited by 402
Pece, S., & Gutkind, J. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006578200 · Cited by 345
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Feng, M., Xiong, G., Cao, Z., Yang, G., Zheng, S., Song, X., You, L., Zheng, L., Zhang, T., & Zhao, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.006 · Cited by 318
Ritprajak, P., & Azuma, M. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.11.014 · Cited by 314
Bellmunt, J., Mullane, S. A., Werner, L., Fay, A. P., Callea, M., Leow, J. J., Taplin, M. E., Choueiri, T. K., Hodi, F. S., Freeman, G. J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv009 · Cited by 276
Abiko, K., Mandai, M., Hamanishi, J., Yoshioka, Y., Matsumura, N., Baba, T., Yamaguchi, K., Murakami, R., Yamamoto, A., Kharma, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2199 · Cited by 221
Lee, Y., Shin, J. H., Longmire, M., Wang, H., Kohrt, H. E., Chang, H. Y., & Sunwoo, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2665 · Cited by 219
Sabbatino, F., Villani, V., Yearley, J. H., Deshpande, V., Cai, L., Konstantinidis, I. T., Moon, C., Nota, S., Wang, Y., Al-Sukaini, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0715 · Cited by 216
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Kaunitz, G. J., Cottrell, T. R., Lilo, M., Muthappan, V., Esandrio, J., Berry, S., Xu, H., Ogurtsova, A., Anders, R. A., Fischer, A. H., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.64 · Cited by 212
Finkelmeier, F., Canli, Ö., Tal, A., Pleli, T., Trojan, J., Schmidt, M., Kronenberger, B., Zeuzem, S., Piiper, A., Greten, F. R., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.002 · Cited by 204
Role of PD-1 in Immunity and Diseases
Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_67 · Cited by 200
Nishimura, H., Honjo, T., & Minato, N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.891 · Cited by 192
Patsoukis, N., Li, L., Sari, D., Petkova, V., & Boussiotis, V. A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00319-13 · Cited by 187
Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
Boussiotis, V. A., Chatterjee, P., & Li, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000059 · Cited by 185
Suzuki, A., Itami, S., Ohishi, M., Hamada, K., Inoue, T., Komazawa, N., Senoo, H., Sasaki, T., Takeda, J., Manabe, M., et al. (2003) · PubMed · Cited by 179
Lu, C., Talukder, A., Savage, N. M., Singh, N., & Liu, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1291106 · Cited by 176
Berthon, C., Driss, V., Liu, J., Kuranda, K., Leleu, X., Jouy, N., Hetuin, D., & Quesnel, B. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0909-y · Cited by 167
Okita, R., Maeda, A., Shimizu, K., Nojima, Y., Saisho, S., & Nakata, M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1986-y · Cited by 159
Efstathiou, J. A., Noda, M., Rowan, A., Dixon, C., Chinery, R., Jawhari, A. U., Hattori, T., Wright, N. A., Bodmer, W. F., & Pignatelli, M. N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3122 · Cited by 151
Clinical Significance of B7‐H1 and B7‐1 Expressions in Pancreatic Carcinoma
Wang, L., Ma, Q., Chen, X., Guo, K., Li, J., & Zhang, M. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0448-x · Cited by 144
PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A
Patsoukis, N., Sari, D., & Boussiotis, V. A. (2012) · Cell Cycle · doi:10.4161/cc.22135 · Cited by 143
Hou, J., Yu, Z., Xiang, R., Li, C., Wang, L., Chen, S., Li, Q., Chen, M., & Wang, L. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.03.005 · Cited by 137
Olmeda, D., Montes, A., Moreno‐Bueno, G., Flores, J. M., Portillo, F., & Cano, A. (2008) · Oncogene · doi:10.1038/onc.2008.118 · Cited by 127
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
Müller, T., Braun, M., Dietrich, D., Aktekin, S., Höft, S., Kristiansen, G., Göke, F., Schröck, A., Brägelmann, J., Held, S. A. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17547 · Cited by 127
Tsao, M., Teuff, G. L., Shepherd, F. A., Landais, C., Hainaut, P. L., Filipits, M., Pirker, R., Chevalier, T. L., Graziano, S. L., Kratze, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx003 · Cited by 117
PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
Scheel, A. H., Ansén, S., Schultheis, A. M., Scheffler, M., Fischer, R. N., Michels, S., Hellmich, M., George, J., Zander, T., Brockmann, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1131379 · Cited by 111
Haendeler, J., Yin, G., Hojo, Y., Saito, Y., Melaragno, M. G., Chen, Y., Sharma, V. K., Heller, M., Aebersold, R. H., & Berk, B. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307317200 · Cited by 97
Cao, Y., Zhang, L., Kamimura, Y., Ritprajak, P., Hashiguchi, M., Hirose, S., & Azuma, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2217 · Cited by 96
Pinato, D. J., Shiner, R. J., White, S. D. T., Black, J. R., Trivedi, P. S., Stebbing, J., Sharma, R., & Mauri, F. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1213934 · Cited by 80
Self-citationPD ‐L1 expression in extrahepatic cholangiocarcinoma
Walter, D. H., Herrmann, E. M., Schnitzbauer, A. A., Zeuzem, S., Hansmann, M. L., Peveling‐Oberhag, J., & Hartmann, S. (2017) · Histopathology · doi:10.1111/his.13238 · Cited by 78
Pinato, D. J., Black, J. R., Trousil, S., Dina, R. E., Trivedi, P. S., Mauri, F. A., & Sharma, R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1358332 · Cited by 72
Self-citationProgrammed Death-1 Shapes Memory Phenotype CD8 T Cell Subsets in a Cell-Intrinsic Manner
Charlton, J. J., Chatzidakis, I., Tsoukatou, D., Boumpas, D. T., Garinis, G. A., & Mamalaki, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201617 · Cited by 60
Targeting the PD-1/PD-L1 axis in non–small cell lung cancer
Kumar, R., Collins, D. C., Dolly, S. O., McDonald, F., O'Brien, M. E. R., & Yap, T. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.002 · Cited by 45
Wankowicz, S. A. M., Werner, L. L., Orsola, A., Novak, J. S. S., Bowden, M., Choueiri, T. K., de Torres, I. M., Moróte, J., Freeman, G. J., Signoretti, S., et al. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.04.102 · Cited by 38
The roles of the PD ‐1/ PD ‐L1 pathway at immunologically privileged sites
Wang, L., Li, Z., Hu, X., Muyayalo, K. P., Zhang, Y., & Liao, A. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12710 · Cited by 36
Baracco, E. E., Pietrocola, F., Buqué, A., Bloy, N., Senovilla, L., Zitvogel, L., Vacchelli, E., & Kroemer, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1139275 · Cited by 27
Cited by
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Metadata
- Authors
- Kythreotou, A., Siddique, A., Mauri, F. A., Bower, M., & Pinato, D. J.
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2017-11-02
- Volume
- 71
- Issue
- 3
- Pages
- 189-194
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W4241749643
- Cited by
- 317
- References
- 88
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.